Soft cationic nanoparticles for drug delivery: production and cytotoxicity of solid lipid nanoparticles (SLNs)

dc.commentsCEB52122por
dc.contributor.authorSilva, Amélia M.por
dc.contributor.authorMartins-Gomes, Carlospor
dc.contributor.authorCoutinho, Tiago E.por
dc.contributor.authorFangueiro, Joana F.por
dc.contributor.authorSanchez-Lopez, Elenapor
dc.contributor.authorPashirova, Tatiana N.por
dc.contributor.authorAndreani, Tatianapor
dc.contributor.authorSouto, Eliana B.por
dc.date.accessioned2019-10-21T08:23:30Z
dc.date.available2019-10-21T08:23:30Z
dc.date.issued2019-10-19
dc.date.updated2019-10-19T11:26:26Z
dc.description.abstractThe surface properties of nanoparticles have decisive influence on their interaction with biological barriers (i.e., living cells), being the concentration and type of surfactant factors to have into account. As a result of different molecular structure, charge, and degree of lipophilicity, different surfactants may interact differently with the cell membrane exhibiting different degrees of cytotoxicity. In this work, the cytotoxicity of two cationic solid lipid nanoparticles (SLNs), differing in the cationic lipids used as surfactants CTAB (cetyltrimethylammonium bromide) or DDAB (dimethyldioctadecylammonium bromide), referred as CTAB-SLNs and DDAB-SLNs, respectively, was assessed against five different human cell lines (Caco-2, HepG2, MCF-7, SV-80, and Y-79). Results showed that the cationic lipids used in SLN production highly influenced the cytotoxic profile of the particles, with CTAB-SLNs being highly cytotoxic even at low concentrations (IC50 < 10 µg/mL, expressed as CTAB amount). DDAB-SLNs produced much lower cytotoxicity, even at longer exposure time (IC50 from 284.06 ± 17.01 µg/mL (SV-80) to 869.88 ± 62.45 µg/mL (MCF-7), at 48 h). To the best of our knowledge, this is the first report that compares the cytotoxic profile of CTAB-SLNs and DDAB-SLNs based on the concentration and time of exposure, using different cell lines. In conclusion, the choice of the right surfactant for biological applications influences the biocompatibility of the nanoparticles. Regardless the type of drug delivery system, not only the cytotoxicity of the drug-loaded nanoparticles should be assessed, but also the blank (non-loaded) nanoparticles as their surface properties play a decisive role both in vitro and in vivo.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion
dc.description.sponsorshipThis research was funded by the Portuguese Science and Technology Foundation, Ministry of Science and Education (FCT/MEC) through national funds, and co-financed by FEDER, under the project references M-ERA-NET/0004/2015 (PAIRED) and UID/AGR/04033/2019 (CITAB), co-financed by FEDER, under the Partnership Agreement PT2020.por
dc.distributioninternationalpor
dc.identifier.citationSilva, Amélia M.; Martins-Gomes, Carlos; Coutinho, Tiago E.; Fangueiro, Joana F.; Sanchez-Lopez, Elena; Pashirova, Tatiana N.; Andreani, Tatiana; Souto, Eliana, Soft cationic nanoparticles for drug delivery: production and cytotoxicity of solid lipid nanoparticles (SLNs). Applied Sciences, 9(20), 4438, 2019por
dc.identifier.doi10.3390/app9204438por
dc.identifier.issn2076-3417por
dc.identifier.urihttps://hdl.handle.net/1822/61816
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherMDPIpor
dc.rightsopenAccesspor
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/por
dc.subjectsurfactantspor
dc.subjectcytotoxicitypor
dc.subjectSLNspor
dc.subjectbiocompatibilitypor
dc.subjectCTABpor
dc.subjectDDABpor
dc.subject.wosScience & Technologypor
dc.titleSoft cationic nanoparticles for drug delivery: production and cytotoxicity of solid lipid nanoparticles (SLNs)por
dc.typearticle
dspace.entity.typePublicationen
oaire.citationIssue20por
oaire.citationVolume9por
oaire.versionVoRpor
sdum.journalApplied Sciencespor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_52122_1.pdf
Tamanho:
554.28 KB
Formato:
Adobe Portable Document Format